RP2 - Reinhardt - Characterizing ATM, MK2 and DNA-PKcs as novel drug targets for the treatment of chemotherapy-resistant high-risk CLL
Christian Reinhardt will give an update on the progress within his work package. We will meet at 16:00 in the main lecture hall of the Max-Planck-Institute for Neurological Research. Wine and cheese will be served. All postdocs, students and technicians are welcome.